(Q38308974)

2 September 2017

1 reference

title

Novel therapeutic options for relapsed hairy cell leukemia (English)

1 reference

2 September 2017

3

Farhad Ravandi

1 reference

2 September 2017

2

Aaron Polliack

1 reference

2 September 2017

Preetesh Jain

1

1 reference

2 September 2017

7 January 2015

1 reference

2 September 2017

1 reference

2 September 2017

56

1 reference

2 September 2017

2264-2272

1 reference

2 September 2017

8

1 reference

2 September 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Hairy cell leukemia: evaluation of the long-term outcome in 121 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Update on the biology and treatment options for hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Fludarabine and rituximab for relapsed or refractory hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Rituximab in relapsed or refractory hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Left behind: should minimal residual disease be treated in hairy cell leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Eradication of minimal residual disease in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

BRAF mutations in hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

BRAF inhibition in refractory hairy-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Efficacy of vemurafenib in hairy-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Tumor adaptation and resistance to RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Analysis of dermatologic events in vemurafenib-treated patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Cutaneous effects of BRAF inhibitor therapy: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

New insights into pre-BCR and BCR signalling with relevance to B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

The B-cell receptor pathway: a critical component of healthy and malignant immune biology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Targeting Bruton's tyrosine kinase in B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Targeting B-cell receptor signaling: changing the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Targeting CD22 in B-cell malignancies: current status and clinical outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Immunotoxins for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.1001988

10.3109/10428194.2014.1001988

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25563425